Relation between Lightscanning and the Histologic and Mammographic Appearance of Malignant Breast Tumors

1992 ◽  
Vol 33 (1) ◽  
pp. 63-68 ◽  
Author(s):  
O. Jarlman ◽  
G. Balldin ◽  
I. Andersson ◽  
M. Löfgren ◽  
A. S. Larsson ◽  
...  
Keyword(s):  
Real Time ◽  
Breast Tumors ◽  
Scar Tissue ◽  
Breast Cancers ◽  
Breast Carcinomas ◽  
Histologic Appearance ◽  
Malignant Breast ◽  
The Difference ◽  
Invasive Carcinomas

The relation between real-time transillumination (lightscanning) and the histologic appearance of 243 breast carcinomas was evaluated. Lightscanning mainly failed in identifying ductal and lobular carcinomas in situ. The result of lightscanning was also poor regarding small, invasive carcinomas. The absorption patterns in elastosis and scar tissue associated with carcinoma played no important role in the ability of lightscanning to identify a cancer. The relation between the lightscanning and mammographic appearance of 85 breast cancers from the same material was also evaluated. Lightscanning performed poorly in identifying tumors characterized by calcifications as compared to tumors with other mammographic appearances. However, the difference was not significant.

scholarly journals Syntaxin-1 and Insulinoma-Associated Protein 1 Expression in Breast Neoplasms with Neuroendocrine Features

2021 ◽  
Vol 27 ◽  
Author(s):  
Sándor Turkevi-Nagy ◽  
Ágnes Báthori ◽  
János Böcz ◽  
László Krenács ◽  
Gábor Cserni ◽  
...  
Keyword(s):  
Chromogranin A ◽  
Neuroendocrine Differentiation ◽  
Breast Tumors ◽  
Type B ◽  
Breast Carcinomas ◽  
Breast Neoplasia ◽  
Invasive Carcinomas ◽  
Diffuse Positivity

Introduction: A subset of breast neoplasia is characterized by features of neuroendocrine differentiation. Positivity for Neuroendocrine markers by immunohistochemistry is required for the diagnosis. Sensitivity and specificity of currently used markers are limited; based on the definitions of WHO Classification of Tumours, 5th edition, about 50% of breast tumors with features of neuroendocrine differentiation express chromogranin-A and 16% express synaptophysin. We assessed the applicability of two novel markers, syntaxin-1 and insulinoma-associated protein 1 (INSM1) in breast carcinomas.Methods: Hypercellular (Type B) mucinous carcinomas, solid papillary carcinomas, invasive carcinomas of no special type with neuroendocrine features and ductal carcinomas in situ of neuroendocrine subtype were included in our study. The immunohistochemical panel included chromogranin A, synaptophysin, CD56, syntaxin-1 and INSM1. The specificity of syntaxin-1 and INSM1 was determined using samples negative for chromogranin A, synaptophysin and CD56.Results: The sensitivity of syntaxin-1 was 84.7% (50/59), with diffuse positivity in more than 60% of the cases. Syntaxin-1 also had an excellent specificity (98.1%). Depending on the definition for positivity, the sensitivity of INSM1 was 89.8% (53/59) or 86.4% (51/59), its specificity being 57.4% or 88.9%. The sensitivities of chromogranin A, synaptophysin and CD56 were 98.3, 74.6 and 22.4%, respectively.Discussion: Syntaxin-1 and INSM1 are sensitive and specific markers of breast tumors with neuroendocrine features, outperforming chromogranin A and CD56. We recommend syntaxin-1 and INSM1 to be included in the routine neuroendocrine immunohistochemical panel.

Expression of steroids and HER2-neu receptors in breast tumors associated with BRCA1 gene mutations

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22223-e22223
Author(s):  
N. A. Zarubina ◽  
V. D. Petrova ◽  
T. V. Sinkina ◽  
S. A. Terekhova ◽  
A. F. Lazarev ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Bilateral Breast Cancer ◽  
Gene Mutations ◽  
Brca1 Gene ◽  
Breast Tumors ◽  
Breast Cancers ◽  
Breast Carcinomas ◽  
Estrogen Receptor Negative

e22223 Background: Hereditary breast carcinomas that are attributable to BRCA1 mutations have their own morphological and immunohistochemical characteristics. This study was aimed to analyze the level of expression of steroids (estrogen and progesterone) and HER2-neu receptors in BRCA1 associated breast cancer. Methods: DNA patterns from 264 patients with hereditary breast cancers (breast cancer diagnosed at the age under 40; bilateral breast cancer; combination of breast and ovarian cancers; 2 and more breast cancers in blood relatives). All the patients were residents of the Altai Territory. BRCA1 gene mutations were registered in 34 patients (12.9%): 5382insC gene mutation - in 28 patients; 300A/C - in 2 patients; 4153del - in 3 patients; 185del - in 1 patient. The frequency of the BRCA1 5382insC allele mutation was 7.3; 300A/C - 0.52; 4153del - 0.26; 185del - 0.83. Immunohistochemical characteristics of BRCA1-associated breast tumors tissue from these patients were investigated. Results: 32 BRCA1-associated breast carcinomas were estrogen receptor- negative; 1 - week positive (H-score 50–100); 1 - moderate positive (H- score 100–200). 33 BRCA1-associated breast carcinomas were progesterone receptor- negative; 1 - positive (H-score 200 and more). HER2-negative were 31 BRCA1-associated breast carcinomas; 2 were week positive (HER2-neu +); 1 - was moderate positive (HER2-neu ++). Conclusion: BRCA1-associated beast carcinomas have been found to be more frequently estrogen receptor-, progesterone receptor-, and HER2- negative. These data show that hereditary breast cancer associated with BRCA1 gene mutations poses poor prognosis. No significant financial relationships to disclose.

scholarly journals Real-time Visualization of Breast Carcinoma in Pathology Specimens From Patients Receiving Fluorescent Tumor-Marking Agent Tozuleristide

2018 ◽  
Vol 143 (9) ◽  
pp. 1076-1083 ◽  
Author(s):  
Suzanne M. Dintzis ◽  
Stacey Hansen ◽  
Kristi M. Harrington ◽  
Lennart C. Tan ◽  
Dennis M. Miller ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Real Time ◽  
Near Infrared ◽  
Infrared Imaging ◽  
Ex Vivo ◽  
Clinical Pathology ◽  
Low Grade ◽  
Imaging Device ◽  
Invasive Carcinomas

Context.— Resection of breast carcinoma with adequate margins reduces the risk of local recurrence and reoperation. Tozuleristide (BLZ-100) is an investigational peptide-fluorophore agent that may aid in intraoperative tumor detection and margin assessment. In this study, fluorescence imaging was conducted ex vivo on gross breast pathology specimens. Objectives.— To determine the potential of tozuleristide to detect breast carcinoma in fresh pathology specimens and the feasibility of fluorescence-guided intraoperative pathology assessment of surgical margins. Design.— Twenty-three patients received an intravenous bolus dose of 6 or 12 mg of tozuleristide at least 1 hour before surgery. Fifteen lumpectomy and 12 mastectomy specimens were evaluated for fluorescence by the site's clinical pathology staff using the SIRIS, an investigational near-infrared imaging device. The breast tissue was then processed per usual procedures. Fluorescent patterns were correlated with the corresponding hematoxylin-eosin–stained sections. Clinical pathology reports were used to correlate fluorescent signal to grade, histotype, prognostic marker status, and margin measurements. Results.— Tozuleristide fluorescence was readily observed in invasive and in situ breast carcinoma specimens. Most invasive carcinomas were bright and focal, whereas in situ lesions demonstrated a less intense, more diffuse pattern. Tozuleristide was detected in ductal and lobular carcinomas with a similar fluorescent pattern. Fluorescence was detected in high- and low-grade lesions, and molecular marker/hormone receptor status did not affect signal. Fluorescence could be used to identify the relationship of carcinoma to margins intraoperatively. Conclusions.— Tumor targeting with tozuleristide allowed visual real-time distinction between pathologically confirmed breast carcinoma and normal tissue.

Differentiation between benign and malignant breast tumors using kinetic features of real-time harmonic contrast-enhanced ultrasound

2012 ◽  
Vol 53 (4) ◽  
pp. 382-388 ◽  
Author(s):  
Ariel Saracco ◽  
Botond K Szabó ◽  
Peter Aspelin ◽  
Karin Leifland ◽  
Brigitte Wilczek ◽  
...  
Keyword(s):  
Real Time ◽  
Breast Tumors ◽  
Contrast Enhanced Ultrasound ◽  
Time Harmonic ◽  
Contrast Enhanced ◽  
Malignant Breast ◽  
Kinetic Features

scholarly journals Comparative sonographic review of benign and malignant breast masses

2018 ◽  
Vol 8 (1) ◽  
pp. 42
Author(s):  
Afodun A M ◽  
Eze E D ◽  
Quadri K K ◽  
Muhammed A O ◽  
Masud M A ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Imaging ◽  
Scar Tissue ◽  
Breast Masses ◽  
Ultrasound Findings ◽  
Malignant Breast ◽  
High Frequency Transducer ◽  
Focal Fibrosis ◽  
Made In

Complex breast masses may appear as suspicious ultrasound findings that usually warrant biopsy. Ductal cell carcinoma in-situ (DCIS) is a form of breast cancer with a non-uniform appearance and malignant potential. A longitudinal review of mammary gland ultrasound (with high frequency transducer) within a three-year period was conducted. Differential diagnosis of fibroadenoma, lactating adenoma, mastitis, galactocele, breast cancer, abscess and “general” masses greater than 16 mm in diameter was stratified. Based on the breast imaging reporting in data system (BIRADS), lesions were classified as benign or malignant and recommendations of cytology made in cases of observed overlap findings. Image sonomorphologic information on mass-echogenic halo and non-uniform orientation were documented; while malignant factors like scar tissue, focal fibrosis and papillomas may be associated with a false positive (conclusion) result. Doppler studies on further mass evaluation is encouraged.

Sign in / Sign up

Export Citation Format

Share Document